NSE மற்றும் BSE-யின் ஒவ்வொரு கார்ப்பரேட் அறிவிப்பும், AI-யால் சில நிமிடங்களில் படிக்கப்பட்டு விளக்கப்படுகிறது — தாக்கம், முக்கிய புள்ளிவிவரங்கள், குறுகிய/நீண்டகாலப் பார்வை, கவனிக்க வேண்டியவை.
நேரலைசமீபத்திய அறிவிப்பு: 2026-10-28 18:13இன்று 0 பகுப்பாய்வு செய்யப்பட்டது
குறிப்பு: இவை NSE பொது அறிக்கைகளின் AI-உருவாக்கிய, கல்வி நோக்கச் சுருக்கங்கள் — ஒவ்வொரு ஆவணத்தையும் ஆதாரமாகக் கொண்டவை, ஆனால் முதலீட்டு ஆலோசனை அல்ல, மேலும் முழுமையற்றதாகவும் இருக்கலாம். அசல் அறிக்கையுடன் சரிபார்க்கவும், செயல்படுவதற்கு முன் SEBI-பதிவு பெற்ற முதலீட்டு ஆலோசகரை அணுகவும்.
Borosil Scientific Approves Rs 70 Cr Glass Tubing Capex; Q2 PAT at Rs 6.25 Cr
Borosil Scientific's Board approved a greenfield/backward-integration capex of up to Rs 70 crore to set up a 20 MT/day Borosilicate 3.3 glass tubing furnace at its Bharuch plant, scheduled for commercial production by March 31, 2028. This capex equals roughly 14.6% of TTM revenue (Rs 478 crore) and ~15.2% of net worth, targeting self-reliance on key raw materials currently imported. Standalone Q2 FY27 revenue from operations grew 4.7% YoY to Rs 104.19 crore (vs Rs 99.48 crore in Q2 FY26). Standalone net profit for the quarter came in at Rs 6.25 crore, down 16.9% YoY from Rs 7.52 crore.
உச்சம் நம்பிக்கை
என்ன மாறியதுBoard approved setting up an in-house glass tubing furnace (20 MT/day) with up to Rs 70 crore capex, while reporting Q2 standalone PAT of Rs 6.25 crore.
ஏன் இது முக்கியம்The project initiates backward integration to eliminate import reliance for primary raw materials, structurally protecting gross margins and securing the supply chain.
Approved capex: up to Rs. 70 croresCapex vs TTM revenue: ~14.6%Furnace capacity: 20 Metric Tonnes (MT) per dayStandalone Q2 Revenue: Rs 10,419.39 lakhsStandalone Q2 PAT: Rs 624.98 lakhs
📅 குறுகிய காலம்Market focus will likely weigh flat-to-soft quarterly standalone PAT against the long-term margin benefits of the announced Rs 70 crore capex program.
📈 நீண்ட காலம்Successful commercialization by March 2028 could improve EBITDA margins by reducing reliance on imported tubing and opening up external sales of surplus output.
⚠ அபாய எச்சரிக்கைகள்
Long execution timeline (targeted completion by March 31, 2028).
Potential debt addition to finance a portion of the Rs 70 crore capex.
👀 கவனிக்க வேண்டியவை
Track financing structure (debt vs internal accruals) and execution milestones toward the March 2028 operational target, along with Gujarat industrial policy subsidy approvals.
Borosil Scientific Approves ₹60 Cr Capex to Expand Glassware Capacity by Over 7x
Borosil Scientific has approved a ₹60 crore capital expenditure to establish an additional glassware manufacturing facility in Bharuch, Gujarat. The expansion will increase specific glassware capacity from ~15 lakh units per annum to ~108 lakh units per annum, a more than sevenfold rise, to meet rising demand from Borosil Limited. The existing capacity is operating at ~87% utilization. Commercial production is slated to begin by March 2027, financed via internal accruals and/or debt, with eligible subsidies to be sought under the Viksit Gujarat Industrial Policy 2026.
உச்சம் நம்பிக்கை
என்ன மாறியதுThe Board approved setting up an additional glassware manufacturing plant at Bharuch with a ₹60 crore capex commitment.
ஏன் இது முக்கியம்With current utilization at ~87%, this 7x capacity ramp addresses supply constraints and deepens supply arrangements with group entity Borosil Limited, driving future revenue growth.
Estimated Capex: ரூ. 60 கோடிCapex vs Net Worth: ~13.0%Current Capacity: ~ 15 lakhs units per annumProposed Capacity: ~ 108 lakhs units per annumCurrent Utilization: ~ 87%Target Commissioning Date: மார்ச் 2027
📅 குறுகிய காலம்Market sentiment should view the sizeable capacity expansion and clear customer demand visibility positively over coming trading sessions.
📈 நீண்ட காலம்Significantly scales Borosil Scientific's manufacturing throughput and long-term earnings base post-commissioning in March 2027, backed by potential state industrial policy subsidies.
⚠ அபாய எச்சரிக்கைகள்
Client/counterparty concentration risk as the expansion specifically caters to demand from Borosil Limited (BL)
Project execution and potential delay risks up to March 2027
Debt addition risk if financing relies heavily on borrowings
👀 கவனிக்க வேண்டியவை
Track progress on project execution milestones, construction timelines ahead of the March 2027 target, and details on debt funding impact on the balance sheet.
Borosil Scientific Q1-FY27: Maintains 75% Market Share in Lab Glassware with 4,500+ SKUs
Borosil Scientific (BOROSCI) released its Q1-FY27 investor presentation, confirming its dominant 75% market share in the Indian laboratory glassware segment. The company reported TTM revenue of ₹467 Cr with an operating margin of 13.3%, supported by a diverse portfolio of 4,500+ SKUs. Strategic growth is focused on the 'LabQuest' instrumentation brand and expanding its export reach, which currently spans 90+ countries. Promoter holding remains stable and high at 68.27% as of June 2026.
உச்சம் நம்பிக்கை
என்ன மாறியதுThe filing provides a comprehensive operational update for Q1-FY27, detailing the company's segment-wise strategy and updated shareholding structure following its 2024 listing.
ஏன் இது முக்கியம்It confirms Borosil's continued dominance in a niche regulated market (pharma/research) where high switching costs provide a competitive moat. The transition from a glassware provider to a full-stack scientific solutions provider is the key long-term narrative.
📅 குறுகிய காலம்The stock may remain range-bound as the presentation reflects steady-state operations without any immediate large-scale order wins or surprises.
📈 நீண்ட காலம்Structural growth depends on the successful scaling of the LabQuest brand and pharmaceutical packaging (vials/ampoules), leveraging the company's deep relationships with research and academic institutions.
⚠ அபாய எச்சரிக்கைகள்
Raw material price volatility (35.8% material cost base)
Low institutional (FII/DII) ownership at 0.5%
Potential margin pressure from labor disputes as seen in previous quarters
👀 கவனிக்க வேண்டியவை
Watch for the revenue ramp-up in the 'LabQuest' instrumentation and Process Systems segments, which are higher-value additions to the core glassware business. Monitor the execution of the ₹40 Cr FY26 capex plan to see if it translates into improved asset turnover.
Borosil Scientific Q1 PAT at ₹4.30 Cr; Board Approves ESOP Discount Increase to 20%
Borosil Scientific reported a consolidated revenue of ₹106.75 Cr for Q1 FY27, marking an 11.2% growth over the ₹95.98 Cr reported in Q1 FY26. The company achieved a turnaround in profitability with a PAT of ₹4.30 Cr, compared to a net loss of ₹4.21 Cr in the same period last year, which was heavily impacted by a ₹6.61 Cr exceptional VRS cost. Additionally, the Board approved amending ESOP schemes to allow secondary market share acquisitions via a Trust and increased the maximum option discount from 10% to 20%.
உச்சம் நம்பிக்கை
என்ன மாறியதுThe company has transitioned from a loss-making quarter (due to one-off labor costs) to profitability and is shifting its ESOP strategy to include secondary market purchases to avoid equity dilution.
ஏன் இது முக்கியம்The results confirm operational recovery and the absence of the labor-related exceptional costs that hampered FY26. The ESOP changes signal a focus on talent retention in a competitive scientific instrumentation market.
📅 குறுகிய காலம்The stock is likely to react positively to the bottom-line turnaround and the normalization of margins following the previous year's labor disputes.
📈 நீண்ட காலம்Long-term growth depends on the successful scaling of the 'LabQuest' instrumentation brand and expansion in the high-margin pharmaceutical packaging segment.
⚠ அபாய எச்சரிக்கைகள்
Moderate revenue growth in the core Scientific segment
Potential increase in employee benefit expenses due to higher ESOP discounts
👀 கவனிக்க வேண்டியவை
Investors should monitor the margin trajectory of the Glassware segment, which returned to a marginal profit of ₹0.19 Cr from a loss of ₹2.27 Cr YoY. Watch for the upcoming shareholder approval for the ESOP amendments and the execution of the ₹40 Cr FY26 capex plan.
Borosil Scientific Q1 FY27: PAT Turns Positive at ₹4.30 Cr; Revenue Up 11.2% YoY
Borosil Scientific reported a consolidated revenue of ₹106.75 Cr for Q1 FY27, marking an 11.2% growth over ₹95.98 Cr in Q1 FY26. The company returned to profitability with a Net Profit of ₹4.30 Cr, compared to a loss of ₹4.21 Cr in the same period last year, which was weighed down by a ₹6.61 Cr exceptional VRS cost. However, on a sequential basis, revenue declined 25.4% from ₹143.17 Cr in Q4 FY26, suggesting seasonal fluctuations. The board also approved increasing the ESOP discount limit to 20% and allowing secondary market share acquisitions through a Trust route.
உச்சம் நம்பிக்கை
என்ன மாறியதுThe company has moved from a loss-making position in the previous year's first quarter to a profitable one, while expanding its ESOP flexibility to include secondary market acquisitions.
ஏன் இது முக்கியம்The results confirm a recovery in the core pharmaceutical packaging (Glassware) segment and steady growth in the Scientific Lab equipment business, which is the company's primary margin driver.
Consolidated Revenue (Q1 FY27): ₹106.75 கோடிConsolidated PAT (Q1 FY27): ₹4.30 கோடிYoY Revenue Growth: 11.2%Scientific Segment Revenue: ₹66.68 கோடிQ1 வருவாய் vs TTM வருவாய்: 22.85%
📅 குறுகிய காலம்The market is likely to view the YoY turnaround in profitability positively, although the significant sequential (QoQ) revenue drop may lead to some caution.
📈 நீண்ட காலம்The structural shift toward higher-margin lab instrumentation (LabQuest) and increased export focus (currently 15% of revenue) remains the key long-term growth thesis.
⚠ அபாய எச்சரிக்கைகள்
Significant sequential revenue decline of 25.4% compared to Q4 FY26
Sensitivity to raw material costs which constitute ~36% of the cost base
👀 கவனிக்க வேண்டியவை
Monitor the margin trajectory in the Glassware segment to see if the return to segment profitability is sustainable. Watch for updates on the ₹40 Cr FY26 capex execution and its impact on H2 FY27 volumes.
📊 கடந்த 7 நாட்கள் — உணர்வு அடிப்படையில் பகுப்பாய்வு செய்யப்பட்ட அறிவிப்புகள்
Borosil Scientific Q4FY26 PAT Surges 216% to ₹27.2 Cr; EBITDA Up 87.6% YoY
Borosil Scientific reported a strong Q4FY26 with consolidated revenue rising 10.6% YoY to ₹143.2 crore. Profitability highlights include an 87.6% YoY jump in EBITDA to ₹32.4 crore and a 216.2% surge in PAT to ₹27.2 crore, partly supported by deferred tax recognition. For the full year FY26, the company achieved a PAT of ₹34.6 crore, up 29.4% YoY, despite one-time exceptional costs of ₹8.53 crore. The company maintains a robust balance sheet with a net cash position of ₹128.1 crore.
முக்கிய அம்சங்கள்
Consolidated Q4FY26 Net Sales grew 10.6% YoY to ₹143.2 crore; FY26 sales up 6.6% to ₹467.3 croreQ4FY26 EBITDA margins expanded significantly to 22.7% from 13.4% in the previous yearLab Consumables segment grew 13.4% YoY in Q4 to ₹80.0 crore, remaining the primary growth driverExceptional items of ₹8.53 crore in FY26 included VRS expenses for the Ambad plant and labor code provisionsMaintained a strong liquidity position with net cash of ₹128.1 crore at the end of FY26
👀 கவனிக்க வேண்டியவை
Investors should focus on the company's ability to scale its Lab Equipment and Process Systems segments, which offer higher growth potential. The strong cash position and market leadership in lab glassware provide a solid margin of safety.
Borosil Scientific to Raise ₹250 Crore and Re-appoints CEO Vinayak Patankar
Borosil Scientific Limited has approved a significant fundraising plan of up to ₹250 crores through various instruments like QIP, FPO, or FCCBs to support future growth. The Board also confirmed the re-appointment of Mr. Vinayak Madhukar Patankar as CEO for a three-year term starting December 2026, ensuring leadership continuity. Additionally, the company reported its audited financial results for FY26 with an unmodified audit opinion. A transition in the Company Secretary role was also announced, with Mr. Ramavtar Sharma taking over from Mr. Sanjay Gupta.
முக்கிய அம்சங்கள்
Board approved fundraising of up to ₹250 crores via QIP, FPO, FCCBs, or other permitted methods.Mr. Vinayak Madhukar Patankar re-appointed as Whole-time Director & CEO for 3 years effective Dec 2, 2026.Audited financial results for the quarter and year ended March 31, 2026, received an unmodified audit opinion.Mr. Ramavtar Sharma appointed as Company Secretary and Compliance Officer effective May 21, 2026.
👀 கவனிக்க வேண்டியவை
Investors should monitor the details and pricing of the ₹250 crore fundraise as it may lead to equity dilution but provides capital for expansion. The re-appointment of the CEO is a positive sign for management stability.
Borosil Scientific Limited (BOROSCI) released its Q3 and 9M FY26 investor presentation, outlining a medium-term growth strategy targeting a 12-14% revenue CAGR. While standalone EBITDA showed growth, consolidated profitability was weighed down by lower sales in the Goel Scientific subsidiary and exceptional expenses totaling approximately ₹8.53 crore. These one-time costs included a ₹6.61 crore Voluntary Retirement Scheme (VRS) settlement and a ₹1.92 crore provision for new labor codes. The company continues to dominate the laboratory glassware market with a 33% share and is pivoting towards higher-margin lab equipment and process sciences.
முக்கிய அம்சங்கள்
Targeting 12-14% Revenue CAGR by expanding LabQuest and Process Sciences verticals.Recognized ₹8.53 crore in exceptional items related to VRS at the Ambad plant and new labor code provisions.Process Systems segment impacted by a ₹3.75 crore revenue reversal in Q3FY26 and deferred high-value orders.Maintains a 33% market share in the ₹490 crore Indian laboratory glassware market.Pharmaceutical sector remains the largest customer base, contributing 58.27% of revenue.
👀 கவனிக்க வேண்டியவை
Investors should monitor the recovery of the Process Systems segment and the stabilization of margins following the one-time restructuring costs. The company's ability to scale its high-margin equipment business will be the primary driver for future valuation re-rating.
Borosil Scientific Q3 FY26 PAT Surges 53% YoY to ₹10.21 Cr; Revenue Up 14%
Borosil Scientific Limited (BOROSCI) reported a strong performance for the quarter ended December 31, 2025, with revenue from operations growing 14.4% YoY to ₹107.12 crore. Net profit (PAT) saw a significant jump of 52.8% YoY to ₹10.21 crore, despite an exceptional charge of ₹1.92 crore related to new labour code provisions. The Scientific Laboratory segment remains the primary profit engine, while the Glassware segment, though still loss-making, showed improvement in its operating performance compared to the previous year. Overall, Profit Before Tax (before exceptional items) grew by 71.8% YoY, indicating strong operational leverage.
முக்கிய அம்சங்கள்
Revenue from operations increased 14.4% YoY to ₹10,712.04 lakhs from ₹9,364.84 lakhs.Net Profit (PAT) grew 52.8% YoY to ₹1,021.07 lakhs compared to ₹668.42 lakhs in the same quarter last year.Scientific Laboratory segment revenue rose to ₹7,316.63 lakhs with a healthy segment profit of ₹2,192.64 lakhs.Glassware segment reported a reduced loss of ₹309.05 lakhs versus a loss of ₹515.83 lakhs YoY.Recognized an exceptional item of ₹191.51 lakhs during the quarter due to the impact of new Government Labour Codes.
👀 கவனிக்க வேண்டியவை
Investors should take note of the robust growth in the core Scientific Laboratory segment which is driving overall profitability. Monitoring the Glassware segment's trajectory toward break-even is recommended as it remains the primary drag on consolidated margins.
BOROSCI: Credit Ratings Reaffirmed; Long-term facilities at CARE A+; Stable
Borosil Scientific Limited's credit ratings have been reaffirmed by CARE Ratings. The long-term bank facilities, reduced from ₹2.10 crores to ₹0.53 crores, are rated CARE A+; Stable. Long-term/Short-term bank facilities, enhanced from ₹97.90 crores to ₹99.47 crores, are rated CARE A+; Stable / CARE A1+. These ratings indicate CARE's opinion on the company's ability to meet its financial obligations.
முக்கிய அம்சங்கள்
Long-term bank facilities reduced to ₹0.53 crores from ₹2.10 croresLong-term/Short-term bank facilities enhanced to ₹99.47 crores from ₹97.90 croresLong-term bank facilities rated CARE A+; StableLong-term/Short-term bank facilities rated CARE A+; Stable / CARE A1+
👀 கவனிக்க வேண்டியவை
The reaffirmed credit ratings suggest stability in Borosil Scientific's financial position. Investors should monitor the company's performance and any further rating updates from CARE.
⚠️இந்தத் தளம் எவ்வாறு உருவாக்கப்படுகிறது: சந்தைத் தரவுப் பக்கங்கள் NSE/BSE வெளியீடுகள் மற்றும் நிறுவனங்களின் தாக்கல்களிலிருந்து தானாகக் கணக்கிடப்படுகின்றன; செய்திக் கட்டுரைகளும் அறிவிப்புப் பகுப்பாய்வுகளும் AI உதவியுடன் எழுதப்படுகின்றன, மனித மேற்பார்வையுடன்: AI உருவாக்குவதை எங்கள் ஆசிரியர்கள் மதிப்பாய்வு செய்கின்றனர். இரண்டிலும் பிழைகள் இருக்கலாம். எந்தவொரு முதலீட்டு முடிவுக்கு முன்பும் அசல் மூலங்களில் சரிபார்க்கவும். முதலீட்டு ஆலோசனை அல்ல; Flash Finance SEBI-பதிவு பெற்றது அல்ல. நாங்கள் AI-ஐ எவ்வாறு பயன்படுத்துகிறோம்
🎁 ஆரம்பகால ஆதரவாளர்களுக்கு மட்டும் · குறுகிய கால சலுகை
எங்கள் AI பங்குச் சந்தை பகுப்பாய்வு: டெலிகிராம், வாட்ஸ்அப்பில் இலவசம்
⚡ 3500+ நிறுவனங்களை நாங்கள் உடனுக்குடன் கண்காணிக்கிறோம். NSE-யில் ஒரு நிறுவன அறிவிப்பு வெளியானதுமே, எங்கள் AI அதைப் படித்து, சுருக்கி, அதன் தாக்கத்தைச் சில நொடிகளில் உங்களுக்குச் சொல்கிறது.
இதுபோன்ற AI பகுப்பாய்வுக்குக் கட்டணத் தளங்கள் ஆண்டுக்கு ₹1,00,000-க்கும் மேல் வசூலிக்கின்றன. எங்கள் சேனல்களில் இது இலவசம்.
